CClinicalTrials.gg
Sign In
CompletedNCT03034096GA-CARESUpdated May 4, 2025

General Anesthetics in CAncer REsection Surgery (GA-CARES) Trial

A Phase 4 interventional study of Propofol and Volatile Agent in Anesthesia, General and Surgical Oncology, sponsored by Stony Brook University. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-04.

Sponsored by Stony Brook University · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2024, 2 years ago, and no results have been posted to the registry.
Phase
Phase 4
Study type
Interventional
Enrollment
1,826
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a large pragmatic multicenter trial comparing maintenance of general anesthesia with total intravenous anesthesia using propofol versus volatile agent (sevoflurane, isoflurane, or desflurane) during cancer surgery. The primary endpoint is all-cause mortality.

02

Conditions studied

  • Anesthesia, General
  • Surgical Oncology

Browse trials for

03

In context

Neoplasms

9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.

This study's enrollment of 1,826 is above the median of 50 across 7,253 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Stony Brook University is the lead sponsor of 191 studies on the registry; 36 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 10 (45%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with known or suspected cancer and scheduled to undergo any of the following oncologic surgical procedures:

    • Lobectomy or pneumonectomy
    • Esophagectomy
    • Radical (total) cystectomy
    • Pancreatectomy
    • Partial hepatectomy
    • Hyperthermic intraperitoneal chemotherapy (HIPEC)
    • Gastrectomy (subtotal or total)
    • Cholecystectomy or bile duct resection

Exclusion criteria

Exclusion Criteria:

  • Age less than 18 years
  • American Society of Anesthesiologist Class 5
  • Projected life expectancy less than 30 days
  • Known or suspected hypersensitivity to either propofol, e.g. egg or soy allergy, or volatile general anesthetic agents
  • Known or suspected history of malignant hyperthermia
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
1,826 participants (actual)

Study arms

  • Experimental
    Propofol infusion

    Maintenance of general anesthesia with propofol infusion

    Drug: Propofol

  • Experimental
    Volatile agent

    Maintenance of general anesthesia with volatile agent (sevoflurane, desflurane, or isoflurane)

    Drug: Volatile Agent

Interventions

  • DrugPropofol

    Maintenance of general anesthesia with propofol infusion

  • DrugVolatile Agent

    Maintenance of general anesthesia with volatile agent (sevoflurane, desflurane, or isoflurane)

06

What researchers measure

Primary outcomes

  1. All-cause mortality

    Time to event

    Time frame: 2 year minimum

Secondary outcomes

  1. Recurrence free survival

    Time to event

    Time frame: Minimum 2 years

  2. All-cause mortality as a binary outcome

    Time frame: 2 years

07

Study locations

5 sites
  • Roswell Park Cancer Center
    Buffalo, New York 14203, United States
  • Long Island Jewish Medical Center
    New Hyde Park, New York 11040, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Stony Brook University Hospital
    Stony Brook, New York 11794-8480, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03034096
Lead sponsor
Stony Brook University
Responsible party
Elliott Bennett-Guerrero (Professor and Vice Chairman, Stony Brook University) — Principal investigator
First posted
Jan 27, 2017
Start date
Jan 31, 2017
Primary completion
Sep 30, 2024
Completion
Sep 30, 2024
Last update
May 4, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Neoplasms→

Other studies from this sponsor

Stony Brook University

Start the discussion